Authors
Raoul Charles Coombes, Karen Page, Raheleh Salari, Robert K Hastings, Anne Armstrong, Samreen Ahmed, Simak Ali, Susan Cleator, Laura Kenny, Justin Stebbing, Mark Rutherford, Himanshu Sethi, Anna Boydell, Ryan Swenerton, Daniel Fernandez-Garcia, Kelly LT Gleason, Katie Goddard, David S Guttery, Zoe J Assaf, Hsin-Ta Wu, Prashanthi Natarajan, David A Moore, Lindsay Primrose, Scott Dashner, Antony S Tin, Mustafa Balcioglu, Ramya Srinivasan, Svetlana V Shchegrova, Alexander Olson, Dina Hafez, Paul Billings, Alexey Aleshin, Farah Rehman, Bradley J Toghill, Allison Hills, Maggie C Louie, Cheng-Ho Jimmy Lin, Bernhard G Zimmermann, Jaqueline A Shaw
Publication date
2019/7/15
Journal
Clinical Cancer Research
Volume
25
Issue
14
Pages
4255-4263
Publisher
American Association for Cancer Research
Description
Purpose
Up to 30% of patients with breast cancer relapse after primary treatment. There are no sensitive and reliable tests to monitor these patients and detect distant metastases before overt recurrence. Here, we demonstrate the use of personalized circulating tumor DNA (ctDNA) profiling for detection of recurrence in breast cancer.
Experimental Design
Forty-nine primary patients with breast cancer were recruited following surgery and adjuvant therapy. Plasma samples (n = 208) were collected every 6 months for up to 4 years. Personalized assays targeting 16 variants selected from primary tumor whole-exome data were tested in serial plasma for the presence of ctDNA by ultradeep sequencing (average >100,000X).
Results
Plasma ctDNA was detected ahead of clinical or radiologic relapse in 16 of the 18 relapsed patients (sensitivity of 89%); metastatic …
Scholar articles
RC Coombes, K Page, R Salari, RK Hastings… - Clinical Cancer Research, 2019